BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30312386)

  • 1. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
    Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
    J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of treatment outcome and relapse in inflammatory bowel disease.
    Kato J; Yoshida T; Hiraoka S
    Expert Rev Clin Immunol; 2019 Jun; 15(6):667-677. PubMed ID: 30873890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
    Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
    Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
    E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
    BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.
    Hosomi S; Yamagami H; Itani S; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    J Crohns Colitis; 2018 Jan; 12(1):87-95. PubMed ID: 28961693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
    Swaminathan A; Borichevsky GM; Edwards TS; Hirschfeld E; Mules TC; Frampton CMA; Day AS; Hampton MB; Kettle AJ; Gearry RB
    J Crohns Colitis; 2022 Dec; 16(12):1862-1873. PubMed ID: 35803583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease.
    Pinto-Lopes P; Melo F; Afonso J; Pinto-Lopes R; Rocha C; Melo D; Macedo G; Dias CC; Carneiro F; Magro F;
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00320. PubMed ID: 33704099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.
    Pinto-Lopes P; Afonso J; Pinto-Lopes R; Rocha C; Lago P; Gonçalves R; Tavares De Sousa H; Macedo G; Camila Dias C; Magro F
    Inflamm Bowel Dis; 2020 Oct; 26(11):1707-1719. PubMed ID: 31912883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.